In low-prevalence settings (e.g., primary care), what stepped NIT strategy do you use to minimize unnecessary hepatology referrals while still safely identifying advanced fibrosis—specifically, where do you place the cut-points for moving from FIB-4 to second-line testing and then to MRE or biopsy?